Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow
Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?
You may also be interested in...
Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.
Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
Lilly's New Year Resolution: Make New Launches Into Blockbusters
Lilly laid out its 2019 financial forecast and commercial and R&D goals during an investor event in New York. While there were no big surprises, the company updated investors on important catalysts in diabetes, immunology, oncology and pain.